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Abstract 
A series of platinum(II) complexes bearing N-heterocyclic carbene NHC ligands 
functionalized by various benzyl moieties were synthesized and characterized. The molecular 
structure of two complexes has been confirmed by X-ray diffraction studies on single crystals. 
Investigation of in vitro cytotoxic activities against various cancer cell lines revealed a strong 
substituent effect: IC50 as low as 0.005 µM were obtained depending on the substituent on the 
benzyl moiety. 
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1. Introduction 
 N-Heterocyclic carbenes (NHCs) are neutral ligands defined as singlet carbenes, in 
which the divalent carbenic center, possessing 6 valence electrons, is connected directly to at 
least one nitrogen atom within the heterocycle.[1] The ease of synthesis and versatility of 
NHCs have contributed to their recognition as ubiquitous ligands in organometallic chemistry 
as evidenced by their wide use ranging from homogeneous catalysis to material sciences.[2] 
More recently, several groups pointed out the importance of N-heterocyclic carbene ligands 
as new structures for the development of metallodrugs.[3,4] Indeed, the high stability of the 
corresponding complexes and the ease of derivatization of the NHC-ligands make them 
suitable candidates for drug development.[5] In addition to their antimicrobial properties, NHC 
complexes have been highlighted as promising agents for anticancer applications. For this 
purpose, several metals have been studied, especially gold, silver, copper, palladium and 
platinum, displaying antitumor activities through various mechanisms that differ from the 
cisplatin used in clinics.[6]  
 In 2010, Marinetti and coworkers demonstrated the efficiency of trans-configured 
platinum complexes of general formula (NHC)PtX2(L) (with L = amine) against cancer cell 
lines.[3b] Cytotoxicity was investigated on leukemia cells and lung cancer cells and showed 
that most complexes exhibit similar or higher activities than cisplatin7 against both cell lines. 
Further investigations on cisplatin resistant cells from human ovarian cancers showed better 
activities than cisplatin and oxaliplatin. Altogether, these results demonstrate the potency of 
trans-Pt(II)-NHC complexes as anticancer agents. Indeed, despite the fact that trans-platinum 
complexes have for long time been overlooked due to the low activity observed with 
transplatin,[8] recent work in the area showed the ability of trans-Pt-NHC complexes to induce 
cytotoxic activities (even on cisplatin resistant cells), which may indicate a different 
mechanism of action than cisplatin. 
Soon after, Marinetti[3b] and others[9,10,11] investigated the effect on cell activity of several N-
heterocyclic carbene platinum complexes. These studies established that both the nature of the 
NHC backbone and the amine that is trans-coordinated to the carbene might influence the 
cytotoxic activity of the corresponding Pt complex. In the search for more potent species, we 
investigated the effect of the nature of the N-benzyl substituent onto the carbene, while 
keeping all substituents identical (i.e. iodide and pyridine ligands). Indeed, Tacke and 
collaborators already pointed out in early 2010 that benzyl-substitution on Ag, Au, Cu or Ru 
NHC complexes could positively influence their biological activities.[12] We report here that 
little change on the benzyl moiety (i.e. introducing p-NO2 or p-Br for example) can 
significantly enhance the cytotoxicity of the complexes.  
 
2. Result and discussion 
All imidazolium salts were prepared using standard and well-established synthetic 
procedures.13 All platinum complexes were then prepared by reaction of the imidazolium salt 
in the presence of platinum dichloride, excess NaI and K2CO3 in dry pyridine at 100°C 
overnight, under nitrogen atmosphere (Scheme 1). The (NHC)PtI2(pyridine) complexes were 
purified by flash chromatography on silica with pentane/dichloromethane as eluent. Figure 1 
displays the molecular structures of all complexes. The 4-position of the benzyl moiety was 
functionalized with either bromo, nitro or formyl substituents, leading to complexes 2, 3 and 
4, respectively. The platinum complex 5 contains polyethylene glycol chains that may 
increase the solubility of the system in aqueous media. Complexes 6 and 7 were substituted 
with 9-methylanthracenyl or 1-methylpyrenyl moieties. Compound 8 is a trinuclear platinum 
complex whereas complexes 9 and 10 have identical substituents on both nitrogen atoms (i.e. 
4-nitrobenzyl and 9-methylanthracenyl, respectively). Isolated yields are ranging from ca. 85-
90 % (complexes 2, 3) to ca. 20 % (complexes 4, 5 and 8). The yield for Pt complex 4 is 
found surprisingly low (19 %). This result may be due to the presence of the benzaldehyde 
moiety that may react with the free carbene (benzoin-type reactivity). Starting from 
PtCl2(COD) as precursor, compound 4 was obtained in 80 % yield. The greater solubility of 
this platinum source may allow the quick trapping of the in situ formed carbene, thus 
preventing side reactions due to the presence of the aldehyde moiety. 
 
Scheme 1. General synthesis of the platinum pyridine NHC complexes. 
 
Figure 1. Molecular structure of the platinum pyridine NHC complexes and complexation 
yield.  
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The formation of the (NHC)Pt-pyridine complexes was confirmed by the typical appearance 
of a signal at δ 135-143 ppm in the 13C NMR spectrum, which was assigned to the carbenic 
carbon, and also by the absence of the resonance peak from the 2H-imidazolium proton in the 
1H NMR spectrum. The molecular structures of compounds 3 and 7 were determined by X-
ray diffraction studies (Figures 2 and 3). The platinum center displays a classical square 
planar geometry where the pyridine is located trans to the carbene. The NHC-platinum bond 
lengths are 1.974(3) Å and 1.969(6) Å, whereas the metal-pyridine bond lengths are 2.089 Å 
in both cases.3b,14 
 
Figure 2. Molecular structure of complex 3. Selected bond distances (Å) and angles (deg): 
C(1)-Pt(1), 1.974(3); Pt(1)-N(4), 2.089(3); Pt(1)-I(1), 2.5887(3); Pt(1)-I(2), 2.5979(3); N(2)-
C(1)-N(1), 105.2(3); N(4)-Pt(1)-I(1), 89.70(7); N(4)-Pt(1)-I(2), 90.69(7); I(1)-Pt(1)-I(2), 
178.436(9); C(1)-Pt(1)N(4), 178.85(12); C(12)-N(4)-C(1)-N(2), -43.0(3); I(1)-I(2)-C(1)-N(4), 
-1.9(4). 
 
 
Figure 3. Molecular structure of the Pt complex 7. Selected bond distances (Å) and angles 
(deg): C(1)-Pt(1), 1.969(6); Pt(1)-N(3), 2.089(5); Pt(1)-I(1), 2.5936(6); Pt(1)-I(2), 2.5863(6); 
N(1)-C(1)-N(2), 104.5(5); N(3)-Pt(1)-C(1), 177.8(3); I(1)-Pt(1)-I(2), 179.46(2); C(26)-N(3)-
C(1)-N(1), 24.30(10); I(1)-I(2)-C(1)-N(3), 1.15(11). 
 
The platinum complexes were evaluated for their IC50 values on a panel of different cancer 
cell lines (MCF7, HCT116, PC3, OV3 and MRC5) and non-cancer cell line (EPC) and the 
results are enlisted in Table 1. Cisplatin was used as reference, and displayed significantly 
lower activity compared to all complexes, except for 5 and 10.15 The introduction of a bromo 
or formyl group in 4-position of the benzyl is not found to affect the overall activities of the 
compounds (compare compound 1 with 2 and 4). Surprisingly, the nitrobenzyl-containing 
complex 3 presented excellent cytotoxicity with IC50 value below 5 nM toward both HCT116 
and MRC5 cancer cells. The presence of an anthracenyl or pyrenyl moiety also lead to 
promising results with IC50 ranging from 0.165 µM to 0.01 µM, whereas introduction of PEG 
chains onto the compound (complex 5) induced a significant drop of the activity. Trinuclear 
platinum complex 8 also displayed a moderate activity compared to mononuclear species.16 
Finally, the bis-nitrobenzyl complex 9 was found less active than the mono-nitrobenzyl 
complex 3 and bis-anthracenyl derivative 10 was inactive, which may be due to its low 
solubility. The enhanced activities may be related to a synergistic effect since the most active 
complexes are combining NHC Pt complexes with a benzylic moiety that is able to intercalate 
into DNA base pairs.[17] 
 
 
Compound MCF7 HCT116 PC3 OV3 MRC5 EPC 
Cisplatin 19.8±0.6 6.4±0.2 10.0±1.0 18±2 12.5±0.1 76±10 
1 0.21±0.02 0.22±0.01 0.35±0.03 - - - 
2 0.36±0.01 0.30±0.02 - - - 0.81±0.02 
3 0.035±0.005 0.005±0.005 0.9±0.2 0.075±0.005 0.005±0.005 0.075±0.005 
4 0.49±0.07 4.6±3.3 0.93±0.03 1.5±0.4 0.60±0.02 1.8±0.2 
5 64.9±0.7 42±2 74±8 67±2 56±2 32±6 
6 0.085±0.005 0.01±0.01 0.035±0.005 0.02±0.01 0.02±0.01 0.085±0.005 
7 0.145±0.005 0.010±0.005 0.16±0.02 0.165±0.005 0.03±0.01 0.11±0.01 
8 8.0±2.0 4.5±0.2 - - - 5.0±2.0 
9 0.36±0.05 0.25±0.01 - - - 0.54±0.08 
10 89±7 40±6 76±1 84±1 47±11 >100 
[a] MCF7, breast carcinoma; HCT116, colon cancer cells; PC3, prostate adenocarcinoma; SK-OV3, human 
ovarian cancer cells; MRC5, human fetus lung cells; EPC, endothelial progenitor cells. 
 
Table 1. Half inhibitory concentrations IC50 (in µM) of the compounds against human cancer 
and non-cancer cell lines (after 72h of incubation).[a] 
 
3. Conclusion 
 
In summary, a series of platinum complexes bearing N-heterocyclic carbene ligands 
functionalized by various benzyl moieties has been synthesized and characterized. The 
complexes show a high stability both in solid state and in solution. The compounds have 
demonstrated variable in vitro activities, which was found to be dependent on the substituents 
on the benzyl moiety. Nonetheless, they usually show cytotoxic activities significantly higher 
than that of cisplatin on 6 different cell lines. Low IC50 values up to 0.005 µM were obtained 
when a nitrobenzyl was introduced onto the NHC ligand. Further studies will focus on 
mechanistic investigations to gain more insights into the therapeutic potential of these 
compounds.  
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